Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Ko on Renal Transplantation Following Tumor Excision

August 12th 2015

Dicken Shiu-Chung Ko, MD, Department of Urology, Massachusetts General Hospital, discusses current evidence of renal transplantation following tumor excision.

Lenvatinib Breakthrough Designation, New Drug Applications for NSCLC, STS, and More

August 7th 2015

Role of Anti-PD-1/PD-L1 Immunotherapy in Bladder Cancer

August 3rd 2015

Results from clinical trials demonstrate that immunotherapy is ready to take center stage in the fight against bladder cancer.

FDA Grants Breakthrough Designation to Lenvatinib for Renal Cell Carcinoma

July 28th 2015

The FDA has granted a breakthrough therapy designation to lenvatinib as a potential treatment for patients with advanced renal cell carcinoma who have received a VEGF-targeted therapy.

Two Positive Phase III RCC Studies, Nivolumab Approved for NSCLC in Europe, and More

July 24th 2015

Optimizing Treatment in Renal Cell Carcinoma

July 21st 2015

Switching Therapies for Progressive Advanced RCC

July 21st 2015

Frontline Treatment Approaches in Advanced RCC

July 21st 2015

Adjuvant Therapy in High-Risk Renal Cell Carcinoma

July 21st 2015

Renal Cell Carcinoma Histologies

July 21st 2015

Promising Treatments on the Horizon for Advanced RCC

July 21st 2015

Treating Oligometastatic Renal Cell Carcinoma

July 21st 2015

Immunotherapy Combinations in Renal Cell Carcinoma

July 21st 2015

PD-1 Inhibition in Advanced Renal Cell Carcinoma

July 21st 2015

Nivolumab Improves Survival in Phase III RCC Trial

July 20th 2015

The phase III CheckMate-025 trial has been halted after an independent panel determined that nivolumab improved overall survival versus everolimus in patients with advanced renal cell carcinoma.

Second-Line Cabozantinib Improves OS, PFS in mRCC

July 20th 2015

Treatment with cabozantinib improved progression-free survival and overall survival compared with everolimus in pretreated patients with metastatic renal cell carcinoma.

Gefitinib Approved for NSCLC, Atezolizumab Shrinks Bladder Tumors, and More

July 19th 2015

Dr. Figlin on Ongoing ADAPT Trial for mRCC

July 14th 2015

Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai, discusses the ongoing phase III ADAPT trial, which examines AGS-003 combined with sunitinib for the treatment of patients with mRCC.

Atezolizumab Achieves Primary Endpoint in Pivotal Phase II Bladder Cancer Study

July 13th 2015

Second-line treatment with atezolizumab (MPDL3280A) has met the primary endpoint of a pivotal phase II study by effectively shrinking tumors in patients with locally advanced or metastatic urothelial bladder cancer.

Dr. Feldman on Link Between Obesity and Risk for RCC

July 9th 2015

Adam S. Feldman, MD, MPH, urologist, Department of Urology, Massachusetts General Hospital, discusses the association between obesity and the risk of developing total and fatal renal cell carcinoma (RCC).